Cranberry powder (CR) is reported to be effective against lower urinary tract symptoms (LUTS) and recurrent urinary tract infections. Benign prostatic hyperplasia (BPH) in men older than 50 years is a common cause of LUTS. Here, we attempted to evaluate if CR is also effective for treating BPH using a BPH-induced rat model, which was orally administered CR. Male Sprague-Dawley rats weighing 200-250 g were randomly divided into the following six groups ( = 9): noncastration group; castration group; BPH group; BPH and cranberry for 8-week (CR8W) group; BPH and cranberry for 4-week (CR4W) group; and BPH and saw palmetto group (saw palmetto). Compared with the BPH group, the CR8W group showed a significant decrease in prostate weight (by 33%), dihydrotestosterone (DHT) levels (by 18% in serum and 28% in prostate), 5-alpha reductase levels (18% reduction of type 1 and 35% of type 2), and histological changes. These results indicate that CR could attenuate BPH by inhibiting 5-alpha reductase and by reducing other biomarkers such as prostate weight and DHT levels. Thus, CR may be an effective candidate for the development of a functional food for BPH treatment. IACUC (USW-IACUC-R-2015-004).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jmf.2020.4779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catalysis activity and chemoselectivity control with the ligand in Ru-H pincer complexes.
Dalton Trans
January 2025
Division of Chemical and Biological Sciences, Ames National Laboratory, Ames, IA 50011, USA.
(PhPNP)Ru(H)(Cl)(CO) serves as a precatalyst to a variety of important catalytic transformations but most improvements have been restricted to the replacement of the CO ligand to the hydride or changing the Ph groups of the pincer for other aryl or alkyl groups. The ligand to the hydride is often another hydride and studies that utilize other ligands in catalysis are limited. In this work, we synthesized a series of [(PhPNP)Ru(H)(CO)(L)][BPh] complexes bearing isonitrile, PMe, or a N-heterocyclic ligand to the Ru-H.
View Article and Find Full Text PDFTechnological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
World J Urol
January 2025
Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Purpose: The purpose of this study was to investigate the efficacy of Transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology in the treatment of benign prostatic hyperplasia (BPH), with a focus on preserving sexual function postoperatively.
Methods: Conducted as a multicenter, prospective, single-blind randomized controlled trial, this study enrolled sexually active male patients with BPH. Participants were randomized into three groups: standard HoLEP (Group A), single-n technology (Group B), and innovative double-n technology (Group C), which emphasizes the preservation of the urethral mucosa and nearby structures.
Background And Objectives: Prostate cancer is the second most frequently diagnosed cancer in men aged 65 years and older globally. The association of prostate cancer with deranged lipid profile and insulin levels is inconsistent and not well understood. This study aimed to analyze the serum levels of lipids, insulin, insulin-like growth factor-1 (IGF-1) and testosterone and to identify their association with the risk of benign prostatic hyperplasia, prostate cancer and its grading.
View Article and Find Full Text PDFComparing surgical techniques: ThuLEP and transurethral BPEP for prostate over 80 grams. Intraoperative and postoperative results. A prospective randomized trial.
Arab J Urol
September 2024
Urology Department, Misr University for Science and Technology, 6th of October City, Egypt.
Background And Purpose: Though TURP remains the primary treatment for BPH, advancements in energy and technology have introduced innovative transurethral surgical options. In this study, we assessed and compared the effectiveness and safety of using thulium laser and bipolar for endoscopic enucleation of prostate exceeding 80 g.
Patients And Methods: Between January 2022 and July 2023, this study enrolled patients with LUTS due to BPH and a prostate size of ≥80 g.
"Laser vaporization of the prostate: A comparative study between ejaculatory preserving and non-ejaculatory preserving technique".
Arab J Urol
July 2024
Faculty of Medicine, Urology Department, Ain Shams University, Cairo, Egypt.
Introduction And Objectives: Laser vaporization techniques have emerged as a prominent alternative to transurethral prostate resection in managing benign prostatic obstruction (BPO). This study focuses on assessing the effectiveness of the ejaculatory preserving laser vaporization of the prostate technique compared to the conventional non-ejaculatory approach in managing BPO.
Patients And Methods: Our study was performed between August 2022 and September 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!